Business Context and Reporting Period
This Form 6-K filing by Scinai Immunotherapeutics Ltd. is dated June 8, 2026, covering the month of June 2026. The document serves as a clarification notice to shareholders regarding the Proxy Statement for the Annual General Meeting of Shareholders scheduled for June 16, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a corporate governance update and does not contain financial statements or performance metrics.
Material Changes
The filing clarifies a discrepancy in the previously issued Proxy Statement regarding Proposal No. 6, which concerns the extension of the Services Agreement with Mr. Mark Germain, Chairman of the Board. The original statement inadvertently stated that Mr. Germain's term would expire on the second anniversary of the Meeting. The correction specifies that his term, as previously approved, extends until the second annual meeting of shareholders after the upcoming June 16, 2026 Meeting. If Proposal No. 6 is approved, the extended Services Agreement will expire at that later date.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary on business operations. The primary risk addressed is the potential for shareholder confusion regarding the duration of the Chairman's Services Agreement, which this filing aims to resolve.
Key Facts for Investor Verification
- Verify the exact expiration date of Mr. Mark Germain's Services Agreement as defined by the "second annual meeting of shareholders after the Meeting" rather than a fixed two-year anniversary.
- Confirm the outcome of Proposal No. 6 at the Annual General Meeting on June 16, 2026.
- Note that this filing incorporates by reference into the company's Registration Statements on Form S-8 and Form F-3.